Novartis investigative site

Pompano Beach, Florida 33060

0 studies enrolling now · 8 studies all time

What they study most

Alzheimer Disease, Chronic Obstructive Pulmonary Disease, Primary Progressive Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)

Studies at this site

• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. — Stopped early
• NVA237 Versus Placebo 12-week Efficacy Study — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline — Completed